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Objective: To characterize fractional exhaled nitric oxide (FeNO) levels that may be  indicative 
of Th2-mediated airway inflammation in patients with chronic obstructive pulmonary disease 
(COPD).
Methods: This single-visit, outpatient study was conducted in 200 patients aged 40 years and 
older with COPD. All patients underwent spirometry and FeNO testing. COPD severity was 
classified according to the Global initiative for chronic Obstructive Lung Disease (GOLD) 
2010 guidelines.
Results: Patients who participated in the study had a mean age of 63.9±11.3 years and a 
mean smoking history of 46±29 pack years. Patients had a mean forced expiratory volume in 
1 second % predicted of 53.9%±22.1%. The percentage of patients classified with COPD sever-
ity Stage I, II, III, and IV was 13%, 40%, 39%, and 8%, respectively. In addition, according to 
current procedural terminology codes, 32% of patients were classified as mixed COPD/asthma, 
26% as COPD/emphysema, and 42% as all other codes. The mean FeNO level for all patients 
was 15.3±17.2 parts per billion (ppb). Overall, 89% of patients had a FeNO ,25 ppb, 8% had a 
FeNO 25–50 ppb, and 3% had a FeNO .50 ppb. The percentages of patients with FeNO in the 
intermediate or high ranges of FeNO were greatest among patients with mixed COPD/asthma 
(intermediate, 11.5%; high, 6.6%) compared with COPD/emphysema (intermediate, 8%; high, 0) 
and all other codes (intermediate, 6.3%; high, 1.3%).
Conclusion: Increases in FeNO were identified in a subset of patients with COPD, particularly 
in those previously diagnosed with both COPD and asthma. Since FeNO is useful for identify-
ing patients with airway inflammation who will have a beneficial response to treatment with 
an inhaled corticosteroid, these data may have important implications for the management of 
COPD patients.
Keywords: fractional exhaled nitric oxide, chronic obstructive pulmonary disease, asthma, 
inhaled corticosteroids
Introduction
Airway inflammation is now recognized as the central mechanism in the pathogenesis 
of asthma and its symptoms. It is also recognized that asthma can co-exist with chronic 
obstructive pulmonary disease (COPD), particularly in older adults, a condition labeled 
the “overlap syndrome” or “Asthma COPD Overlap Syndrome (ACOS)”.1 Asthma itself 
may, in fact, be a risk factor for the development of COPD.1 While airway inflamma-
tion in COPD is generally thought to be primarily characterized by CD8+ lymphocytes, 
macrophages, and neutrophils, some patients with COPD may have features of asthma 
and, subsequently, a component of Th2-mediated airway inflammation.2





Th2-mediated airway inflammation can be assessed 
through the measurement of fractional exhaled nitric oxide 
(FeNO).3 Nitric oxide gas is produced in the epithelial cells 
of the bronchial wall in response to interleukin (IL) 4 and 
IL13 via the STAT-6 pathway.3 Measurement of FeNO is 
the only clinical test for evaluating Th-2 mediated airway 
inflammation that can be performed quickly and easily, 
providing consistent and accurate results in clinical practice 
at the point-of-care. The measurement of FeNO in human 
breath with the NIOX MINO® device (AerocrineAB, Solna, 
Sweden) provides a rapid, noninvasive, and inexpensive tool 
to assess airway inflammation.
The American Thoracic Society recently published an 
evidence-based clinical practice guideline that strongly rec-
ommends the use of FeNO for the following applications:4 
1) diagnosis of eosinophilic airway inflammation in indi-
viduals with non-specific lower respiratory symptoms, 
2) determining the likelihood of steroid responsiveness in 
individuals with chronic non-specific lower respiratory symp-
toms possibly due to airway inflammation, and 3) monitoring 
eosinophilic airway inflammation in patients with asthma. 
However, the exact role of FeNO in patients with established 
COPD remains to be defined. While there have been a number 
of preliminary studies on measuring FeNO in COPD, litera-
ture defining the role of FeNO in patients with established 
COPD is minimal. Furthermore, many COPD patients have 
difficulty expectorating sputum and/or can only produce poor 
quality sputum samples, which are not adequate to accurately 
quantify eosinophilic cells. The objective of the current study 
was to characterize FeNO levels that may be indicative of 
airway inflammation in patients with COPD.
Methods
Patient population
Eligible participants included men and women aged 40 years 
and older with COPD, including chronic bronchitis and 
emphysema, and/or a mixed diagnosis of asthma/COPD. 
Participants were excluded from participation in the study 
if they had other chronic obstructive lung disease including 
but not limited to cystic fibrosis, bronchiectasis, obliterative 
bronchiolitis, ciliary dyskinesia, post-viral bronchial hyper-
responsive syndrome, vocal cord dysfunction, rhinosinusitis, 
non-eosinophilic asthma, and reactive airways dysfunction 
syndrome. Other conditions that excluded patients from par-
ticipation included pneumothorax, fractured rib(s), or signs of 
cardiac instability (eg, a recent myocardial infarction, unstable 
angina, unstable vital signs, or acute shortness of breath, chest 
tightness, or chest pain). Demographic information, selected 
medical history information, and baseline characteristics 
including height, weight, body mass index (BMI), smoking 
status, pack years of tobacco use, and current medication 
information were obtained from eligible participants.
Study design
This was a pilot, observational (no treatment allocation), 
 multicenter, single-visit, outpatient study. This study was 
conducted at two sites within the University of North  Carolina, 
Chapel Hill, North Carolina, Department of Respiratory 
and Critical Care Medicine between June 18, 2012 and 
October 19, 2012. An institutional review board at the study 
center approved the study protocol and all participants signed 
a written consent document prior to study enrollment.
Spirometry measurements
Subsequent to the FeNO measurement, patient spirometry 
values were collected, according to American Thoracic Soci-
ety guidelines.5 In the event that spirometry preceded the 
FeNO test, a waiting period of not less than 20 minutes was 
imposed to separate the two procedures. Parameters collected 
were forced expiratory volume in 1 second (FEV
1
), forced 
vital capacity (FVC), forced expiratory flow between 25% 
and 75% of vital capacity (FEF
25–75
), forced expiratory flow 
at 50% of vital capacity (FEF
50%
), and peak expiratory flow 
(PEF). The severity of patients’ COPD based on spirom-
etry values and Global initiative for chronic Obstructive 
Lung  Disease (GOLD) guidelines was recorded. Once all 
information had been collected and all procedures had been 
performed, the patient was discharged from the clinic, as 
their study participation was completed.
FeNO measurements
Patients refrained from eating, drinking (except water), and/or 
smoking for at least 1 hour prior to the FeNO  measurement. 
Training on the use of the device (NIOX MINO®; Aero-
crineAB) to perform FeNO measurements was conducted 
by the study staff according to the guidelines in the user 
manual. Patients were instructed to inhale to total lung capac-
ity and then exhale into the device for 10 seconds. A visual 
incentive was activated upon exhalation to assist patients 
to maintain a constant flow rate. Exhalations performed at 
a pressure of 10 to 20 cm H
2
O were required to maintain a 
50 mL/second flow rate and resulted in display of a FeNO 
value. Each patient was allowed up to eight attempts to 
perform a single valid FeNO measurement. Controls on the 
device ensured that expiration efforts below the fixed flow 
rate requirements did not result in display of a FeNO value. 
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Table 1 Patient demographics and baseline characteristics
Demographic parameter Per protocol 
population 
(N=191)




Female, n (%) 111 (58.1%)
Primary race, n (%)
 Caucasian 160 (83.8%)
 African American 27 (14.1%)
 Asian 0
 American Indian or Alaska Native 2 (1%)
 Other 2 (1%)
ethnicity
 Not Hispanic or Latino 189 (99.0%)
 Hispanic or Latino 2 (1%)












Smoking status, n (%)
 Never smoked 9 (4.7%)
 Current smoker 58 (30.4%)
 Past smoker 124 (64.9%)




Note: N refers to the per protocol population, upon which analyses were conducted; 
n refers to the smaller sub-group populations.
The FeNO value  displayed on the device was not intended 
for (nor incorporated in) clinical care of the patient during 
the study visit.
Aerocrine provided training for the principal investiga-
tor and available staff on the use of the device during study 
initiation. All instruments were labeled according to the US 
Food and Drug Administration guidelines and all devices 
were returned to the sponsor at the end of the study.
Safety measurements
Adverse events and serious adverse events were recorded.
Statistical analyses
As this was an observational study, no formal statistical 
analyses or hypothesis testing were performed. The safety 
population included all participants who were enrolled in 
the study. Adverse events and the ability to perform a FeNO 
measurement were described in this population. The per pro-
tocol population was defined as all participants in the safety 
population who met all inclusion and exclusion criteria and 
were also able to perform spirometry and a FeNO measure-
ment. All other data displays and summaries were performed 
on data from the per protocol population.
Results
Two hundred participants were screened for this study. Nine 
patients were excluded from the per protocol population. The 
primary reason for exclusion from the per protocol population 
was inability to perform either FeNO or spirometry (eight 
patients). One additional patient had asthma, but not COPD, 
and was also excluded. The final per protocol population 
comprised 191 patients. All 191 patients in the per protocol 
population completed the study.
Patient demographic information is presented in Table 1. 
The mean age was 63.9 years (range 42–94 years) and 58.1% 
were women. The vast majority of patients were non-Hispanic 
(99.0%) and Caucasian (83.8%) and predominantly smok-
ers (past smokers-64.9%; current smokers-30.4%). Of the 
past smokers, 96/124 (77%) reported the time since quitting 
(mean-13.7 years; range 0–43 years). The most common 
medications used for pulmonary/allergy conditions were 
short-acting beta-agonists (83.8%), inhaled corticosteroid 
(ICS) plus long-acting beta-agonist (LABA) bronchodila-
tor combination products (75.4%), and long-acting anti-
muscarinic antagonists (69.6%) (Figure 1).
There were no reported issues or problems with the use 
of the device. A total of 194/200 (97.0%) of the participants 
had a successful FeNO test.
Spirometry and FeNO measurements
Spirometry results are reported in Table 2. As expected in 
this population, mean FEV
1
 values indicated obstructive lung 




FeNO levels parts per billion (ppb) are summarized by 
GOLD severity stage in Figure 2. Mean (median, interquartile 
range [IQR]) FeNO level in the per protocol population was 
15.3±17.18 ppb (12.0 ppb, IQR 8–17); mean values ranged 
from 3 ppb to 183 ppb. Median (IQR) FeNO levels were gener-
ally similar by GOLD stage: Stage I, 12 (9.5, 16.75); Stage II, 
13 (9, 18.25); Stage III, 11 (7, 15); and Stage IV, 11.5 (6.75, 
18.25). Median (IQR) FeNO levels were also similar by sex 
(male, 12 [8, 21.5]; female, 12 [7.75, 16.25]), race (Caucasian, 
12 [8, 17]; African-American, 11 [8, 16.5]); and smoking 
status (Table 3). FeNO levels categorized by low (,25 ppb), 
intermediate ($25 but #50 ppb), and high (.50 ppb) levels 
are summarized by ICS use, smoking history, and international 
classification of diseases (ICD)-9 codes in Table 3.
The majority of patients (89.0%) had low FeNO levels, 
regardless of their ICS use, smoking history, or ICD 9 codes. 
Only 21/191 (11%) had intermediate or high FeNO levels. 





















Figure 1 Pulmonary and allergy medications used in over 10% of patients.
Note: Patients could be using more than one of the medications.
Abbreviations: SABA, short-acting Beta-2 agonists; LABA, long-acting Beta-2 agonists; ICS, inhaled corticosteroids; LAMA, long-acting muscarinic antagonists; SAMA, 
short-acting muscarinic antagonists.
diagnostic ICD-9 code that included asthma. The group with 
the ICD-9 code that included asthma was found to have the 
highest FeNO value (mean 20.5±27.57 ppb) compared to 
mean values of 12.9 ppb in the other ICD-9 groups. There 
were three patients with intermediate or high FeNO levels 
who were not taking ICS.
Safety
Two patients experienced an adverse event that was con-
sidered serious, but unrelated to the FeNO maneuver. 
Table 2 Spirometry results for the per-protocol population
Parameter Values
Fev1 (L) 





Fev1 % predicted 



































Abbreviations: SD, standard deviation; Fev1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; FEF, forced expiratory flow; PEF peak expiratory flow. 
0
n=24 n=77 n=74































Stage IV: very severe
Figure 2 FeNO levels by GOLD stage of COPD severity.
Abbreviations: FeNO, fractional exhaled nitric oxide; GOLD, Global initiative for 
chronic Obstructive Lung Disease; COPD, chronic obstructive pulmonary disease; 
ppb, parts per billion; Fev1, forced expiratory volume in 1 second; pred, predicted.
A total of 161/191 (84%) of patients were taking ICS, either 
alone or in combination with a LABA, though only 61/191 
(32%) had an ICD-9 code that included asthma.
Twenty-one patients had intermediate (n=16) or high 
(n=5) FeNO levels and 4/5 (80%) of those with high levels 
and 7/16 (44%) of those with intermediate levels had a 
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The first patient, a 53-year-old non-smoking African- American 
woman, experienced headache and chest discomfort, which 
worsened shortly after leaving the clinic. The second patient, 
a 46-year-old Caucasian woman, complained of “retaining 
CO
2
”, felt that her movements were slightly jerky, and was 
unable to perform a FeNO measurement.
Discussion
The results from this observational study suggest that 
increases in FeNO do occur in patients with COPD. Although 
the majority of patients had low levels of FeNO in this study, 
11% of patients had intermediate or high FeNO levels with 
no overall observable relationship between GOLD classifica-
tion and FeNO level.
In this study of 191 COPD patients, 61 (32%) had both a 
diagnosis of asthma and COPD, which is consistent with the 
number reported by other investigators who suggested that 
the ACOS exists in 20%–33% of COPD patients and that its 
prevalence increases with age.6–8 Although the percentage of 
billing codes of asthma was slightly higher in this study than 
in other studies, the overall findings in the current study are 
in line with those reported in other epidemiologic studies.6,8 
This population has traditionally been excluded from clini-
cal trials, but studies have shown that COPD patients can 
be difficult to differentiate from asthma patients due to their 
positive bronchodilator responses.9 Patients with COPD have 
long been known to have positive responses to methacholine 
challenge.10
These data suggest that FeNO levels may be helpful in 
identifying patients with ACOS. FeNO levels in this pilot 
study were substantially higher in patients with mixed 
asthma/COPD compared with emphysema alone or COPD 
without a concurrent diagnosis of asthma or emphysema. 
Identifying an eosinophilic inflammatory component in 
patients with COPD may lead to better treatment choices 
in this heterogeneous disease. In a prospective study of 
49 ex-smoking COPD patients with an acute exacerbation, 
Soter et al reported that FeNO was a strong predictor of 
sputum eosinophilia at exacerbation.11 There was a signifi-
cant positive correlation between the percentage of sputum 
eosinophils and FeNO concentrations both at exacerbation 
and hospital discharge, regardless of whether or not patients 
received ICS at hospital admission. Furthermore, COPD 
patients with eosinophilic airway inflammation responded 
better to treatment with bronchodilators and corticosteroids 
compared to patients with predominantly neutrophilic airway 
inflammation.11
Several studies have now shown that patients with COPD 
who have sputum eosinophilia upon exacerbation may have 
greater corticosteroid responsiveness.12–14 A reduction in 
eosinophilic airway inflammation has also been shown to 
reduce the number of future COPD exacerbations.2 Other 
investigators have determined that FeNO levels may be 
predictive of greater treatment response to corticosteroids 
and bronchodilator therapy.15,16 Antus et al reported that in 
58 COPD patients with acute exacerbation, patients with 
increased FeNO at the time of exacerbation responded bet-
ter to treatment with corticosteroids and bronchodilators.15 
Similarly, after 4 weeks of treatment with ICS in a study 
of 60 ex-smokers with severe COPD, ICS responders had 
significantly higher baseline FeNO levels compared with 
non-responders.16 Akamatsu et al studied 14 patients with 
COPD and found that FeNO .35 ppb and evidence of atopy 
predicted improvement in FEV
1
 with ICS/LABA when 
added to tiotropium.17 Zietkowski et al evaluated the useful-
ness of FeNO in predicting corticosteroid responsiveness 
Table 3 FeNO level by inhaled corticosteroid use, smoking status, and ICD 9 code category
FeNO  
category






















,25 ppb 27 (90.0%) 143 (88.8%) 8 (80%) 105 (85.4%) 56 (96.6%) 50 (82.0%) 46 (92.0%) 74 (92.5%) 170 (89.0%)
$25 ppb 
or #50 ppb
2 (6.7%) 14 (8.7%) 1 (10%) 13 (10.6%) 2 (3.4%) 7 (11.5%) 4 (8.0%) 5 (6.3%) 16 (8.4%)
.50 ppb 1 (3.3%) 4 (2.5%) 1 (10%) 5 (4.1%) 0 (0%) 4 (6.6%) 0 1 (1.3%) 5 (2.6%)
Mean FeNO  
level, ppb (SD)
– – – – – 20.5 (27.57) 12.9 (7.40) 12.9 (8.21) 15.3 (17.18)
Median FeNO  
level, ppb (IQR)
12 (8.75, 17.75) 13 (9, 20.5) 10 (7, 14.75) – – – 12 (8, 17)
Note: N refers to the per protocol population, upon which analyses were conducted; n refers to the smaller sub-group populations.
Abbreviations: FeNO, fractional exhaled nitric oxide; ICD, International Classification of Diseases; ICS, inhaled corticosteroid; ppb, parts per billion; SD, standard deviation; 
IQR, interquartile range; COPD, chronic obstructive pulmonary disease.





in 47 patients with COPD.18 These investigators found a 
significant correlation between baseline FeNO and response 
to corticosteroids following 2 months of treatment.18
Taken together, these data suggest that measurement of 
FeNO may be useful for identifying patients with COPD who 
will have a beneficial response to corticosteroids. The vast 
majority of patients in the current pilot study (75%) received 
treatment with an ICS/LABA combination therapy as recom-
mended by COPD standard of care.1 Monotherapy with ICS 
is not currently recommended in the treatment of COPD. 
However, given that ICS treatment can be costly and may 
place patients with COPD at greater risk for complications 
such as pneumonia, osteoporosis, glaucoma, and cataracts, it 
would be ideal if ICS treatment could be targeted to patients 
with comorbid Th-2 mediated inflammation. These patients 
would be more likely to respond to treatment with an ICS 
or ICS combination therapy.
In this pilot study, many patients who were taking 
ICS still had elevated levels of FeNO. This observation 
elicits further study questions: 1) if the ICS dose had been 
increased in these patients, would FeNO levels or outcomes 
have been improved? 2) if FeNO levels were not elevated, 
does the patient truly need ICS therapy? 3) do FeNO levels 
predict future risk in COPD as they have been shown to 
predict in asthma?19 4) can that risk be mitigated by adjust-
ing ICS dose in COPD as it can be in asthma?20,21 5) can 
FeNO assist in determining medication choices to optimize 
patient outcomes in COPD? These unanswered questions 
regarding the role of FeNO measurement in determining a 
treatment plan for patients with COPD should be addressed 
in future, well-controlled studies. Another unstudied factor to 
consider is the effect of smoking on FeNO levels. Smoking 
is known to suppress exhaled nitric oxide, which may lead 
to misinterpretation of FeNO levels in COPD.22 However, 
more data are needed to better understand the magnitude of 
reduction of FeNO that smoking can cause. Also, Barnes et al 
emphasized the importance of measuring FeNO in patients 
with COPD exacerbations since insufficient data exist in the 
assessment of airway inflammation in patients with COPD 
during exacerbations.23
In conclusion, data from this pilot study demonstrated that 
increases in FeNO values can be observed in patients with 
COPD. Measurement of FeNO provides the physician with 
useful information to determine if a patient with COPD has 
underlying Th-2 mediated inflammation that may indicate 
ACOS (ie, asthma occurring along with COPD) and may have 
implications in the management of patients with COPD.
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